Float Short %

34.62

Margin Of Safety %

Put/Call OI Ratio

0.53

EPS Next Q Diff

-0.25

EPS Last/This Y

-0.3

EPS This/Next Y

0.33

Price

22.18

Target Price

42.55

Analyst Recom

1.33

Performance Q

17.15

Relative Volume

0.79

Beta

-0.27

Ticker: ANAB

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-06-02	ANAB	21.83	1.06	0.03	11434
2025-06-03	ANAB	23.54	1.00	4.13	11802
2025-06-04	ANAB	21.25	0.98	0.63	12001
2025-06-05	ANAB	21.18	1.00	1.32	12086
2025-06-06	ANAB	23.69	0.99	0.66	12128
2025-06-09	ANAB	23.24	1.00	0.26	12094
2025-06-10	ANAB	23.93	0.99	0.02	12123
2025-06-11	ANAB	23.36	1.00	0.57	12106
2025-06-12	ANAB	23.45	1.00	9.00	12100
2025-06-13	ANAB	23.32	1.00	9.00	12100
2025-06-16	ANAB	23.91	1.00	1.03	12098
2025-06-17	ANAB	23.85	1.01	0.19	12101
2025-06-18	ANAB	23.34	1.01	2.86	12128
2025-06-20	ANAB	23.18	1.01	0.80	12146
2025-06-23	ANAB	22.78	0.51	0.16	3946
2025-06-24	ANAB	23.31	0.51	5.50	3952
2025-06-25	ANAB	23.22	0.51	0.00	3961
2025-06-26	ANAB	23.36	0.51	999.99	3961
2025-06-27	ANAB	22.46	0.52	6.50	3990
2025-06-30	ANAB	22.2	0.53	0.00	4018
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-06-02	ANAB	21.83	8.4	-25.6	-5.68
2025-06-03	ANAB	23.52	8.4	-46.1	-5.68
2025-06-04	ANAB	21.28	8.4	-10.1	-5.68
2025-06-05	ANAB	21.14	8.4	-27.9	-5.68
2025-06-06	ANAB	23.73	8.4	-57.3	-5.42
2025-06-09	ANAB	23.19	9.6	-28.2	-5.42
2025-06-10	ANAB	23.95	9.6	-39.7	-5.42
2025-06-11	ANAB	23.62	9.6	-29.7	-5.42
2025-06-12	ANAB	23.41	9.6	-31.0	-5.42
2025-06-13	ANAB	23.26	9.6	-31.3	-5.42
2025-06-16	ANAB	23.86	9.6	-37.7	-5.42
2025-06-17	ANAB	23.87	9.6	-32.5	-5.42
2025-06-18	ANAB	23.39	9.6	-28.8	-5.42
2025-06-20	ANAB	23.17	9.6	-30.8	-5.42
2025-06-23	ANAB	22.80	9.6	-29.2	-5.42
2025-06-24	ANAB	23.33	9.6	-37.5	-5.42
2025-06-25	ANAB	23.25	9.6	-32.2	-5.42
2025-06-26	ANAB	23.42	9.6	-34.1	-5.42
2025-06-27	ANAB	22.44	9.6	-24.1	-5.42
2025-06-30	ANAB	22.18	9.6	-30.0	-5.42
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-06-02	ANAB	2.66	25.99	33.35
2025-06-03	ANAB	2.66	25.99	33.35
2025-06-04	ANAB	3.02	25.99	33.35
2025-06-05	ANAB	3.02	25.99	33.35
2025-06-06	ANAB	3.02	25.99	33.35
2025-06-09	ANAB	3.02	26.14	33.35
2025-06-11	ANAB	3.02	26.14	34.78
2025-06-12	ANAB	3.02	26.14	34.78
2025-06-13	ANAB	3.02	26.14	34.78
2025-06-16	ANAB	3.02	22.72	34.78
2025-06-17	ANAB	3.02	22.72	34.78
2025-06-18	ANAB	3.02	22.72	34.78
2025-06-19	ANAB	3.02	22.72	34.78
2025-06-20	ANAB	2.80	22.72	34.78
2025-06-24	ANAB	2.76	22.87	34.83
2025-06-25	ANAB	2.76	22.87	34.83
2025-06-26	ANAB	2.76	22.87	34.62
2025-06-27	ANAB	2.76	22.87	34.62
2025-06-30	ANAB	2.76	22.90	34.62
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-1.28

Avg. EPS Est. Current Quarter

-1.55

Avg. EPS Est. Next Quarter

-1.53

Insider Transactions

2.76

Institutional Transactions

22.9

Beta

-0.27

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

46.3

Max Drawdown 5-Year %

-69.3

Target Price

42.55

P/E

Forward P/E

PEG

P/S

5.83

P/B

19.83

P/Free Cash Flow

EPS

-4.84

Average EPS Est. Cur. Y

-5.42

EPS Next Y. (Est.)

-5.09

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-125.7

Relative Volume

0.79

Return on Equity vs Sector %

-437.2

Return on Equity vs Industry %

-418.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.53

EBIT Estimation

-30

AnaptysBio, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 136

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

stock quote shares ANAB – AnaptysBio Inc Stock Price stock today

news today ANAB – AnaptysBio Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch ANAB – AnaptysBio Inc yahoo finance google finance

stock history ANAB – AnaptysBio Inc invest stock market

stock prices ANAB premarket after hours

ticker ANAB fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ANAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y